Opposing inflammatory biomarker responses to sleep disruption in cancer patients before and during oncological therapy

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: id:"swepub:oai:DiVA.org:hj-58656" > Opposing inflammato...

1 av 1
Föregående post
Nästa post
Till träfflistan

Oliva, DelmyLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Ryhov Cty Hosp, Sweden (författare)

Opposing inflammatory biomarker responses to sleep disruption in cancer patients before and during oncological therapy

Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

2022-09-21
Frontiers Media S.A.2022
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:hj-58656
https://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-58656URI
https://doi.org/10.3389/fnins.2022.945784DOI
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-189330URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

BackgroundSleep disruption is known to be highly prevalent in cancer patients, aggravated during oncological treatment and closely associated with reduced quality of life, therapeutic outcome and survival. Inflammatory factors are associated with sleep disruption in healthy individuals and cancer patients, but heterogeneity and robustness of inflammatory factors associated with sleep disruption and how these are affected by oncological therapy remain poorly understood. Furthermore, due to the complex crosstalk between sleep-, and therapy-associated factors, including inflammatory factors, there are currently no established biomarkers for predicting sleep disruption in patients undergoing oncological therapy. MethodsWe performed a broad screen of circulating biomarkers with immune-modulating or endocrine functions and coupled these to self-reported sleep quality using the Medical Outcomes Study (MOS) sleep scale. Ninety cancer patients with gastrointestinal, urothelial, breast, brain and tonsillar cancers, aged between 32 and 86 years, and scheduled for adjuvant or palliative oncological therapy were included. Of these, 71 patients were evaluable. Data was collected immediately before and again 3 months after onset of oncological therapy. ResultsSeventeen among a total of 45 investigated plasma proteins were found to be suppressed in cancer patients exhibiting sleep disruption prior to treatment onset, but this association was lost following the first treatment cycle. Patients whose sleep quality was reduced during the treatment period exhibited significantly increased plasma levels of six pro-inflammatory biomarkers (IL-2, IL-6, IL-12, TNF-a, IFN-g, and GM-CSF) 3 months after the start of treatment, whereas biomarkers with anti-inflammatory, growth factor, immune-modulatory, or chemokine functions were unchanged. ConclusionOur work suggests that biomarkers of sleep quality are not valid for cancer patients undergoing oncological therapy if analyzed only at a single timepoint. On the other hand, therapy-associated increases in circulating inflammatory biomarkers are closely coupled to reduced sleep quality in cancer patients. These findings indicate a need for testing of inflammatory and other biomarkers as well as sleep quality at multiple times during the patient treatment and care process.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Neurovetenskaper hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Neurosciences hsv//eng
cancer
sleep
inflammation
oncological therapy
biomarkers

Biuppslag (personer, institutioner, konferenser, titlar ...)

Andersson, Bengt-ÅkeJönköping University,HHJ, Avdelningen för naturvetenskap och biomedicin,Jonkoping Univ, Sweden(Swepub:hj)andben (författare)
Lewin, FreddiLinköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Ryhov Cty Hosp, Sweden(Swepub:liu)n/a (författare)
Jensen, LasseLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Klinisk farmakologi(Swepub:liu)larje86 (författare)
Linköpings universitetAvdelningen för kirurgi, ortopedi och onkologi (creator_code:org_t)

Sammanhörande titlar

Ingår i:Frontiers in Neuroscience: Frontiers Media S.A.161662-45481662-453X

Internetlänk

Hitta via bibliotek

Frontiers in Neuroscience (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Oliva, Delmy; Andersson, Bengt ...; Lewin, Freddi; Jensen, Lasse

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Medicinska och f ...; och Neurovetenskaper

Artiklar i publikationen: Frontiers in Neu ...

Av lärosätet: Jönköping University; Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se